Dustin J. Maly

The paper measures variant effects across the MAPK pathway in human cells, revealing how cell context influences variant function and identifying 14,412 previously unknown dominant negative variants.

This paper measures ERK activation state using a sequencing-based assay to identify BRAF variants affecting signaling and drug sensitivity.

This study identifies how Raf inhibitor potency varies with Raf activity and shows that cobimetinib enhances sensitivity to DFG-out inhibitors by disrupting autoinhibited Raf-Mek complexes.

The paper develops a method to discover new effector handles for proteome editing by combining de novo protein design with multiplex screening, identifying handles for degradation and stabilization of target proteins.

This paper introduces LABEL-seq, a platform for multimodal profiling of protein variants, revealing how cancer-related mutations affect activity, interactions, and druggability.

This paper introduces a chemically-controlled DNA binding switch (ciCas9) to enable temporal modulation of Cas9-based effectors, demonstrating its application in base editors and transcriptional activators.

This paper introduces dead-RNAs (dRNAs) to suppress unwanted CRISPR/Cas9 off-target and HDR-corrected site cleavage, enabling precise genome editing.

This study shows that inhibiting IRE1α kinase/RNase reduces lung fibrosis in mice by blocking the terminal UPR, with two compounds demonstrating efficacy in preventing and reversing fibrosis.